GenTrust’s Recursion Pharmaceuticals RXRX Stock Holding History

GenTrust’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$55K	Buy	15,000 +756	+5%	+$2.52K	﹤0.01%	200
2026 Q1	$43.7K	Buy	14,244 +1,807	+15%	+$6.98K	﹤0.01%	280
2025 Q4	$50.9K	Sell	12,437 -2,563	-17%	-$12.7K	﹤0.01%	280
2025 Q3	$73.2K	Hold	15,000	–	–	﹤0.01%	210
2025 Q2	$75.9K	Hold	15,000	–	–	﹤0.01%	175
2025 Q1	$79.3K	Hold	15,000	–	–	﹤0.01%	188
2024 Q4	$101K	Hold	15,000	–	–	﹤0.01%	200
2024 Q3	$98.8K	Hold	15,000	–	–	﹤0.01%	200
2024 Q2	$113K	Hold	15,000	–	–	0.01%	178
2024 Q1	$150K	Hold	15,000	–	–	0.01%	135
2023 Q4	$148K	Hold	15,000	–	–	0.01%	127
2023 Q3	$115K	Buy	+15,000	New	+$150K	0.01%	131

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

GenTrust's RXRX Position: Q2 2026 in Review

GenTrust increased its Recursion Pharmaceuticals (RXRX) stake by 5.3% in Q2 2026, buying an estimated $2.52K and bringing the position to 15,000 shares worth $55K. The position accounts for ﹤0.01% of the portfolio, ranked #200.

GenTrust first reported a position in RXRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $150K in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

GenTrust held 15,000 shares of Recursion Pharmaceuticals worth $55K as of Q2 2026.
GenTrust bought 756 Recursion Pharmaceuticals shares in Q2 2026, an estimated $2.52K.
Recursion Pharmaceuticals made up ﹤0.01% of GenTrust's portfolio in Q2 2026, its #200 holding.
GenTrust first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
GenTrust's Recursion Pharmaceuticals position peaked at $150K in Q1 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on GenTrust's 13F filing for Q2 2026, filed 6 Aug 2026.